The role of the microbiota and metabolites in the treatment of pulmonary fibrosis with UC-MSCs: Integrating fecal metabolomics and 16S rDNA analysis
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) ameliorate bleomycin-induced pulmonary fibrosis symptoms in mice by exerting anti-inflammatory effects and mitigating pulmonary fibrosis through the modulation of gut microbiota disorders and their metabolism. These findings offer novel insights into the potential mechanisms and clinical utility of stem cell therapy for pulmonary fibrosis.
Authors
- Yizhou Lin (ORCID: https://orcid.org/0009-0007-9249-8107)
- Yukai Luo
- Wenzhao Cheng (ORCID: https://orcid.org/0000-0002-0394-2082)
- Xiaojing Zhang (ORCID: https://orcid.org/0000-0003-1795-4399)
- Jun Liu (ORCID: https://orcid.org/0000-0003-0097-078X)
- Shuang Zhou (ORCID: https://orcid.org/0000-0002-4188-5496)
- Yiming Zeng (ORCID: https://orcid.org/0000-0001-5635-3006)
Institutions
- Fujian Medical University (CN)
- Longyan University (CN)
- Second Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1371/journal.pone.0313989
- Citations
- 8
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 12.15
Funders
- Innovative Research Group Project of the National Natural Science Foundation of China
- National Natural Science Foundation of China